Papillary Thyroid Carcinoma With Multiple Bone Metastases — When Bone Resorption Inhibitors Have Not Controlled Bone Pain
Papillary thyroid carcinoma (PTC) that has spread to multiple bone sites presents a significant challenge for pain management. Inhibition of bone resorption is recommended as an initial strategy in this population, but pain control is not always achieved with that approach alone.
Bone resorption inhibitors — bisphosphonates or denosumab — were administered with the goal of reducing bone pain associated with the metastases. When adequate pain reduction is not achieved, escalation to the next treatment step is indicated.
After bone resorption inhibitors have failed to control pain, the protocol addresses painful or high-fracture-risk bone lesions through radiation-based therapy and/or interventional radiology techniques. The primary clinical goal is pain relief, which can begin within 48–72 hours of treatment. The complete regimen — including specific modalities, indications, and sequencing criteria — is available in the full protocol.
Inhibition of bone resorption should be considered in TC patients with multiple bone metastases.
If surgery is not feasible, bone lesions associated with pain or a high fracture risk should be treated with fractionated (20 Gy in five fractions or 30 Gy in 10 fractions) or single-fraction (8 Gy) EBRT and/or with interventional radiology techniques, including cementoplasty and thermal ablation.
For spinal cord compression in a patient whose life expectancy exceeds 6 months, longer fractionation schedules (e.g. 30 Gy in 10 fractions over 2 weeks) are recommended.
Pain relief is often achieved 48–72 h after treatment, although it may take up to 1 month.
View source ↗